期刊
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
卷 53, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jddst.2019.101133
关键词
Polydopamine; Alendronate; Targeting anti-osteosarcoma; Modification; Paclitaxel nanoparticles
资金
- National Natural Science Foundation of China [U1401223]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-1-012]
- National Major Scientific and Technological Special Project for Significant New Drugs Development [2015ZX09501005]
To improve the treatment effects of chemotherapy on osteosarcoma, we synthesized novel nanoparticles (NPs) coated with polydopamine (PDA) and grafted by alendronate (ALN) as ligand. Dopamine polymerization is a versatile modification technique that is not limited by the lack of functional groups on the compound surfaces and does not alter the chemical properties. The PDA-NPs were successfully conjugated with a typical surface modifier, which had a specific affinity for osteosarcoma cells: alendronate (ALN), as a targeting paclitaxel (PTX) carrier. We fabricated the NPs with average particle size of 255.12 +/- 1.560 nm, zeta potential of -17.4 +/- 3.27 and PDI value of 0.193 +/- 0.026. The nanoparticles were stable in physiological saline, isotonic glucose (5% glucose), phosphate buffered saline (PBS, PH 7.4) and plasma and displayed sustained drug release behavior. Furthermore, the targeting nanoparticles exhibited a stronger in vitro cytotoxicity against K7M2 wt osteosarcoma cells compared to free nanoparticles. In vivo study demonstrated that the targeting NPs could accumulate to a greater extent within the tumor than nontargeted nanoparticles, which prominently decreased the side effects of PTX and achieved better therapeutic efficacy than PTX injection (8 mg/kg, i.v.) (82.51% versus 66.63%). Therefore, the PTX-PDA-ALN-NPs represent a potential drug for osteosarcoma-targeted therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据